Alzecure får god draghjälp av European Innovation Council och kan fortsätta planeringen av en fas 2a...
The recent share price reaction is an overreaction.
Cardeon, som investerar i life science-bolag i tidigt skede, har flera attraktiva innehav som gjort ...
Redeye cuts its forecasts and Base Case following a Q4 with negative ARR growth yet improved EBITDA-...
Organic sales growth of 11% y-o-y in Q4 Security Solutions grows despite loss of major contract Prof...
Redeye is positive about the multiple ascending dose data being in line with previous single ascendi...
Suominen claims it was able to resolve the operational issues it faced during Q3, but this was not y...
Careium wins 12-year Norwegian contract Contract worth SEK 24m, ~2% of '26e net sales Trading at 9.
EMB Mission Bound AB, före detta Embark Group, (”EMB” eller ”Bolaget”) meddelade den 4 mars år 2025 ...
Redeye sees a soft Q4 report from BrightBid. While costs decrease and EBITDA-CAPEX increase, negativ...
Redeye updates its estimates and fair value range following Ngenic’s Q4 report last week.
Redeye provides an update on Scandinavian ChemoTech following the Q4 2024 report.
Hifab Group AB (”Hifab”, ”Koncernen” eller ”Bolaget”) meddelade den 4 mars år 2025 att Bolaget har t...
Redeye gives a short comment on yesterday’s news that Acadia and Saniona announced positive initial ...
7% premium to last 3-month average, slightly below last close Equates to 2.
